| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S H Sindrup, K Brøsen, L F Gram, J Hallas, E Skjelbo, A Allen, G D Allen, S M Cooper, G Mellows, T C Taske. The relationship between paroxetine and the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. vol 51. issue 3. 1992-04-13. PMID:1531950. |
the relationship between the selective serotonin reuptake inhibitor paroxetine and the sparteine oxidation polymorphism was investigated in a combined single-dose (30 mg) and steady-state (30 mg/day for 2 weeks) study including a panel of nine extensive metabolizers and eight poor metabolizers of sparteine. |
1992-04-13 |
2023-08-11 |
human |
| S H Sindrup, K Brøsen, L F Gra. Pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clinical pharmacology and therapeutics. vol 51. issue 3. 1992-04-13. PMID:1531951. |
pharmacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. |
1992-04-13 |
2023-08-11 |
Not clear |
| A clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor (SSRI). The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531815. |
a clinical profile of paroxetine: a novel selective serotonin reuptake inhibitor (ssri). |
1992-04-08 |
2023-08-11 |
Not clear |
| A Kie. A double-blind, placebo-controlled study of paroxetine in depressed outpatients. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531818. |
paroxetine is an investigational antidepressant that acts through selective inhibition of serotonin reuptake at the synapse. |
1992-04-08 |
2023-08-11 |
Not clear |
| W F Boyer, J P Feighne. An overview of paroxetine. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531819. |
paroxetine is a novel phenylpiperidine compound that acts as a selective serotonin reuptake inhibitor (ssri). |
1992-04-08 |
2023-08-11 |
human |
| K Rickels, J Amsterdam, C Clary, I Fox, E Schweizer, C Weis. The efficacy and safety of paroxetine compared with placebo in outpatients with major depression. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531820. |
paroxetine, a phenylpiperidine derivative, is an antidepressant that selectively inhibits serotonin reuptake. |
1992-04-08 |
2023-08-11 |
Not clear |
| J L Claghor. The safety and efficacy of paroxetine compared with placebo in a double-blind trial of depressed outpatients. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531821. |
paroxetine is an investigational antidepressant that appears to act by selectively blocking neuronal serotonin uptake. |
1992-04-08 |
2023-08-11 |
Not clear |
| W T Smith, V Glaudi. A placebo-controlled trial of paroxetine in the treatment of major depression. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531822. |
paroxetine is a phenylpiperidine compound that selectively inhibits neuronal serotonin uptake in man. |
1992-04-08 |
2023-08-11 |
Not clear |
| L F Fabr. A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531823. |
paroxetine is a novel antidepressant that selectively inhibits neuronal reuptake of serotonin. |
1992-04-08 |
2023-08-11 |
Not clear |
| J P Feighner, W F Boye. Paroxetine in the treatment of depression: a comparison with imipramine and placebo. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531824. |
paroxetine is a selective serotonin reuptake inhibitor with significant antidepressant properties. |
1992-04-08 |
2023-08-11 |
Not clear |
| R K Shrivastava, S H Shrivastava, N Overweg, C L Blumhard. A double-blind comparison of paroxetine, imipramine, and placebo in major depression. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531825. |
results from a single-center, 6-week, double-blind, randomized prospective study of paroxetine, a selective serotonin reuptake inhibitor; imipramine; and placebo are reported. |
1992-04-08 |
2023-08-11 |
Not clear |
| J B Cohn, C S Wilco. Paroxetine in major depression: a double-blind trial with imipramine and placebo. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531826. |
paroxetine is a selective serotonin reuptake inhibitor which is being developed as an antidepressant. |
1992-04-08 |
2023-08-11 |
Not clear |
| D L Dunner, J B Cohn, T Walshe, C K Cohn, J P Feighner, R R Fieve, J P Halikas, J T Hartford, E D Hearst, E C Settl. Two combined, multicenter double-blind studies of paroxetine and doxepin in geriatric patients with major depression. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531827. |
paroxetine is an antidepressant that acts through selective inhibition of serotonin reuptake. |
1992-04-08 |
2023-08-11 |
Not clear |
| I F Tulloch, A M Johnso. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531829. |
the pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. |
1992-04-08 |
2023-08-11 |
Not clear |
| I F Tulloch, A M Johnso. The pharmacologic profile of paroxetine, a new selective serotonin reuptake inhibitor. The Journal of clinical psychiatry. vol 53 Suppl. 1992-04-08. PMID:1531829. |
paroxetine is a highly potent and selective inhibitor of serotonin reuptake, being more potent in vitro than fluoxetine, fluvoxamine, and sertraline. |
1992-04-08 |
2023-08-11 |
Not clear |
| K M Dewar, T A Reader, L Grondin, L Descarrie. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse (New York, N.Y.). vol 9. issue 1. 1992-04-08. PMID:1724575. |
[3h]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. |
1992-04-08 |
2023-08-11 |
rat |
| K M Dewar, T A Reader, L Grondin, L Descarrie. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse (New York, N.Y.). vol 9. issue 1. 1992-04-08. PMID:1724575. |
in both species, there was an excellent correlation between regional 5-ht levels and specific [3h]paroxetine binding (r = 0.87 in the rat and 0.96 in the rabbit). |
1992-04-08 |
2023-08-11 |
rat |
| K M Dewar, T A Reader, L Grondin, L Descarrie. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse (New York, N.Y.). vol 9. issue 1. 1992-04-08. PMID:1724575. |
considering the available quantitative data on the number of 5-ht nerve cell bodies and axon terminals in different regions of the rat brain, it appears likely that the high amount of [3h]paroxetine binding in the midbrain raphe region and ventral mesencephalic tegmentum reflects the presence of 5-ht uptake sites on 5-ht nerve cell bodies and dendrites as well as axon terminals. |
1992-04-08 |
2023-08-11 |
rat |
| K M Dewar, T A Reader, L Grondin, L Descarrie. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region. Synapse (New York, N.Y.). vol 9. issue 1. 1992-04-08. PMID:1724575. |
in other brain regions, the heterogeneous distribution of [3h]paroxetine binding parallels that of the number of 5-ht axon terminals, emphasizing the potential usefulness of this radioligand as a marker of 5-ht innervation density. |
1992-04-08 |
2023-08-11 |
rat |
| F Hassanyeh, E F Marshal. Measures of serotonin metabolism in anorexia nervosa. Acta psychiatrica Scandinavica. vol 84. issue 6. 1992-04-01. PMID:1724337. |
blood from all patients was analysed for monoamine oxidase, serotonin (5-ht), 5-hydroxyindoleacetic acid (5-hiaa), homovanillic acid (hva), tryptophan and platelet paroxetine binding. |
1992-04-01 |
2023-08-11 |
human |